- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made).
2.—(1) This paragraph defines “presentation of health service medicine” and related terms for the purposes of these Regulations.
(2) “Presentation of health service medicine” means—
(a)a presentation of unbranded generic health service medicine,
(b)a presentation of made special health service medicine,
(c)a presentation of imported special health service medicine, or
(d)a presentation of any other health service medicine.
(3) “Presentation of unbranded generic health service medicine” means a particular unbranded generic health service medicine which may be distinguished from all other such medicines by reference to—
(a)its active ingredients,
(b)its strength,
(c)its physical form,
(d)its unit dose (if applicable),
(e)its method of administration (if applicable),
(f)its freeness (if applicable),
(g)its pack size, and
(h)the type of its packaging.
(4) “Presentation of made special health service medicine” means a particular made special health service medicine which may be distinguished from all other such medicines by reference to—
(a)its active ingredients,
(b)its strength,
(c)its physical form,
(d)its unit dose (if applicable), and
(e)its method of administration (if applicable).
(5) “Presentation of imported special health service medicine” means a particular imported special health service medicine which may be distinguished from all other such medicines by reference to—
(a)its active ingredients,
(b)its strength,
(c)its physical form,
(d)its unit dose (if applicable),
(e)its method of administration (if applicable),
(f)its freeness (if applicable),
(g)its pack size, and
(h)the type of its packaging.
(6) “Presentation of other health service medicine” means a particular health service medicine which may be distinguished from all other other health service medicines by reference to—
(a)its active ingredients,
(b)its strength,
(c)its physical form,
(d)its unit dose (if applicable),
(e)its method of administration (if applicable),
(f)its freeness (if applicable),
(g)its pack size, and
(h)the type of its packaging.
(7) In paragraph (5) “other health service medicine” means a health service medicine which is not an unbranded generic health service medicine or a special health service medicine.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: